-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122

Benzinga·08/14/2026 14:23:07
语音播报
Barclays analyst Eliana Merle maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $120 to $122.